Lv62
2010 积分 2024-09-23 加入
Overcoming adaptive therapy resistance in AML by targeting immune response pathways
12天前
已完结
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
1个月前
已关闭
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
1个月前
已完结
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
1个月前
已完结
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
1个月前
已完结
Approaching a therapeutic inflection point for FLT3-mutated AML
1个月前
已完结
Targeting FLT3 for treating diseases: FLT3 inhibitors
1个月前
已完结
Biomarkers as Surrogate Endpoints in Drug Development: Finding Their Right Place
1个月前
已完结
Acute myeloid leukaemia
3个月前
已完结
皖公网安备34019202002308
